These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35747566)

  • 61. Detection of micrometastasis of neuroblastoma to bone marrow and tumor dissemination to hematopoietic autografts using flow cytometry and reverse transcriptase-polymerase chain reaction.
    Tsang KS; Li CK; Tsoi WC; Leung Y; Shing MM; Chik KW; Lee V; Ng MH; Yuen P
    Cancer; 2003 Jun; 97(11):2887-97. PubMed ID: 12767104
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Method for DNA Ploidy Analysis Along with Immunophenotyping for Rare Populations in a Sample using FxCycle Violet.
    Tembhare P; Badrinath Y; Ghogale S; Subramanian PG
    Curr Protoc Cytom; 2017 Apr; 80():6.38.1-6.38.15. PubMed ID: 28369766
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Potential therapeutic biomarkers in plasma cell myeloma: a flow cytometry study.
    Zheng W; Liu D; Fan X; Powers L; Goswami M; Hu Y; Lin P; Medeiros LJ; Wang SA
    Cytometry B Clin Cytom; 2013; 84(4):222-8. PubMed ID: 23450831
    [TBL] [Abstract][Full Text] [Related]  

  • 64. CD56 Expression Is an Important Prognostic Factor in Multiple Myeloma Even with Bortezomib Induction.
    Skerget M; Skopec B; Zadnik V; Zontar D; Podgornik H; Rebersek K; Furlan T; Cernelc P
    Acta Haematol; 2018; 139(4):228-234. PubMed ID: 29920491
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Understanding the Bioactivity and Prognostic Implication of Commonly Used Surface Antigens in Multiple Myeloma.
    Lebel E; Nachmias B; Pick M; Gross Even-Zohar N; Gatt ME
    J Clin Med; 2022 Mar; 11(7):. PubMed ID: 35407416
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients.
    Paiva B; Gutiérrez NC; Chen X; Vídriales MB; Montalbán MÁ; Rosiñol L; Oriol A; Martínez-López J; Mateos MV; López-Corral L; Díaz-Rodríguez E; Pérez JJ; Fernández-Redondo E; de Arriba F; Palomera L; Bengoechea E; Terol MJ; de Paz R; Martin A; Hernández J; Orfao A; Lahuerta JJ; Bladé J; Pandiella A; Miguel JF;
    Leukemia; 2012 Aug; 26(8):1862-9. PubMed ID: 22333880
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Immunophenotypic heterogeneity of normal plasma cells: comparison with minimal residual plasma cell myeloma.
    Liu D; Lin P; Hu Y; Zhou Y; Tang G; Powers L; Medeiros LJ; Jorgensen JL; Wang SA
    J Clin Pathol; 2012 Sep; 65(9):823-9. PubMed ID: 22685235
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases.
    Tembhare PR; Yuan CM; Venzon D; Braylan R; Korde N; Manasanch E; Zuchlinsky D; Calvo K; Kurlander R; Bhutani M; Tageja N; Maric I; Mulquin M; Roschewski M; Kwok M; Liewehr D; Landgren O; Stetler-Stevenson M
    Leuk Res; 2014 Mar; 38(3):371-6. PubMed ID: 24462038
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Immunophenotype in multiple myeloma cells detected by multiparameter flow cytometry].
    Cao FF; Chen F; Hu YP; Zhang JH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Jun; 20(3):620-3. PubMed ID: 22739168
    [TBL] [Abstract][Full Text] [Related]  

  • 70. High-sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma.
    Almeida J; Orfao A; Ocqueteau M; Mateo G; Corral M; Caballero MD; Blade J; Moro MJ; Hernandez J; San Miguel JF
    Br J Haematol; 1999 Oct; 107(1):121-31. PubMed ID: 10520032
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Immunophenotypic analysis of Waldenstrom's macroglobulinemia.
    San Miguel JF; Vidriales MB; Ocio E; Mateo G; Sánchez-Guijo F; Sánchez ML; Escribano L; Bárez A; Moro MJ; Hernández J; Aguilera C; Cuello R; García-Frade J; López R; Portero J; Orfao A
    Semin Oncol; 2003 Apr; 30(2):187-95. PubMed ID: 12720134
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Immunophenotypic studies of monoclonal gammopathy of undetermined significance.
    Olteanu H; Wang HY; Chen W; McKenna RW; Karandikar NJ
    BMC Clin Pathol; 2008 Nov; 8():13. PubMed ID: 19040735
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Immunophenotype and DNA cell content in multiple myeloma.
    San Miguel JF; Garcia-Sanz R; Gonzalez M; Orfao A
    Baillieres Clin Haematol; 1995 Dec; 8(4):735-59. PubMed ID: 8845570
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Prognostic Value of Association of Copy Number Alterations and Cell-Surface Expression Markers in Newly Diagnosed Multiple Myeloma Patients.
    Dragoș ML; Ivanov IC; Mențel M; Văcărean-Trandafir IC; Sireteanu A; Titianu AA; Dăscălescu AS; Stache AB; Jitaru D; Gorgan DL
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35886877
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Flow cytometric immunophenotypic characteristics of 36 cases of plasma cell leukemia.
    Kraj M; Kopeć-Szlęzak J; Pogłód R; Kruk B
    Leuk Res; 2011 Feb; 35(2):169-76. PubMed ID: 20553988
    [TBL] [Abstract][Full Text] [Related]  

  • 76. CD24 Is a Prognostic Marker for Multiple Myeloma Progression and Survival.
    Gross Even-Zohar N; Pick M; Hofstetter L; Shaulov A; Nachmias B; Lebel E; Gatt ME
    J Clin Med; 2022 May; 11(10):. PubMed ID: 35629039
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Role of CD138, CD56, and light chain immunohistochemistry in suspected and diagnosed plasma cell myeloma: A prospective study.
    Dass J; Arava S; Mishra PC; Dinda AK; Pati HP
    South Asian J Cancer; 2019; 8(1):60-64. PubMed ID: 30766858
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Characterization of circulating myeloma tumor cells by next generation flowcytometry in scleromyxedema patient: a case report.
    Taha RY; Hasan S; Ibrahim F; Chantran Y; Sabah HE; Sivaraman S; Bozom IA; Sabbagh AA; Garderet L; Omri HE
    Medicine (Baltimore); 2020 Jul; 99(27):e20726. PubMed ID: 32629647
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Phenotypic characterization of the human myeloma cell growth fraction.
    Robillard N; Pellat-Deceunynck C; Bataille R
    Blood; 2005 Jun; 105(12):4845-8. PubMed ID: 15741217
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile.
    Paiva B; Paino T; Sayagues JM; Garayoa M; San-Segundo L; Martín M; Mota I; Sanchez ML; Bárcena P; Aires-Mejia I; Corchete L; Jimenez C; Garcia-Sanz R; Gutierrez NC; Ocio EM; Mateos MV; Vidriales MB; Orfao A; San Miguel JF
    Blood; 2013 Nov; 122(22):3591-8. PubMed ID: 24072855
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.